Siemens Healthineers stock enters investor roadshow week

Siemens Healthineers stock entered a European investor roadshow week on Monday, November 9, after the medical-technology group reported its fiscal 2026 results on November 5. The company's investor-relations calendar lists a J.P. Morgan roadshow in London on November 9, followed on Tuesday by a UBS roadshow in Frankfurt, a J.P. Morgan roadshow in Paris and the UBS European Healthcare Conference in London. Siemens Healthineers confirms the schedule on its investor-relations page.

Strong Finish, More Cautious Outlook

The company reported comparable revenue growth of 4.0 percent for fiscal 2026, adjusted EBIT of around 3.8 billion euros and an adjusted EBIT margin of 16.2 percent. Adjusted basic earnings per share reached 2.42 euros, while free cash flow was around 2.4 billion euros. Siemens Healthineers proposed an unchanged dividend of 1.00 euro per share.

The fourth quarter supplied the strongest operating momentum in the reported year. Comparable revenue growth reached 5.9 percent, with Imaging up 10.0 percent and Precision Therapy up 4.8 percent. Diagnostics declined 4.2 percent on a comparable basis, and its adjusted EBIT margin was 5.4 percent. The figures are from the company's fiscal 2026 results release, published November 5.

For fiscal 2027, Siemens Healthineers expects comparable revenue growth of 4.0 to 5.0 percent. Adjusted basic earnings per share are forecast in a range of 2.20 to 2.40 euros, below the reported fiscal 2026 level. The outlook gives investors a direct benchmark for the roadshow discussions, particularly as the group works to improve Diagnostics while sustaining momentum in Imaging.

Execution Becomes the Investor Test

Management described the next phase as a sharper portfolio focus, with the core business strengthened and Diagnostics positioned for a standalone future. That strategy adds a structural dimension to the financial outlook: investors must assess both the near-term margin path and the company's ability to execute its portfolio changes without weakening growth.

Siemens Healthineers stock traded at 44.22 euros on Lang & Schwarz at 11:12 CET on Monday, November 9, 0.99 percent below the Xetra close of Friday, November 6, at 44.66 euros. Investors can follow the real-time quote of Siemens Healthineers stock.

The DAX provides the relevant German market backdrop for the stock's investor discussions; current DAX market reports cover the broader index.

The next scheduled company date is publication of the fiscal 2026 annual report on November 25, followed by a virtual Bank of America CEO call on December 10. More news and analyses on Siemens Healthineers stock will track the outlook and portfolio transition.